Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 5 of 14

10. Invivyd Inc (NASDAQ:IVVD)

Number of Hedge Fund Holders In Q3 2024: 16

Invivyd Inc (NASDAQ:IVVD) is a biopharma company that makes antibody-based treatments. The primary target is COVID-19.

The stock has surged significantly so far in 2025 due to Q4 2024 net product revenue for PEMGARDA surging 48% quarter-over-quarter to $13.8 million. This is on top of Q3’s $9.3 million.

Moreover, operating expenses fell 55% to $32 million in Q4 2024, and this was driven by reduced manufacturing costs.

The company ended 2024 with $69.3 million in cash and $10.9 million in accounts receivable.

The consensus price target of $7.89 implies 692.71% upside.

IVVD stock is up 84.32% year-to-date.

Page 5 of 14